Opko Health OPK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Diagnostics | $60.64M-3.6% | $62.92M-20.0% | $78.68M+3.2% | $76.27M-4.5% | $79.87M+1.7% | |
| Pharmaceutical | $148.44M+3.8% | $143.02M-3.3% | $147.89M+5.2% | $140.54M+1.0% | $139.2M-0.5% | |
| Operating Income by Business | ||||||
| Pharmaceutical | -$93.26M+5.2% | -$98.34M-9.6% | -$89.76M+8.2% | -$97.77M-4.1% | -$93.88M-8.2% | |
| Total Assets by Business | ||||||
| Diagnostics | $1.55B-8.3% | $1.68B-7.9% | $1.83B-7.1% | $1.97B-6.3% | $2.1B-6.0% | |
| Pharmaceutical | $5.3B— | —— | —— | —— | —— | |
| Selling General And Administrative Expense by Business | ||||||
| Diagnostics | $117.5M-9.1% | $129.3M-11.9% | $146.81M-21.2% | $186.25M-5.6% | $197.38M-3.8% | |
| Pharmaceutical | $55.36M+2.8% | $53.87M+2.2% | $52.71M-3.8% | $54.81M-1.6% | $55.68M-4.0% | |
| Research And Development Expense by Business | ||||||
| Diagnostics | $1.41M-13.8% | $1.64M-11.1% | $1.84M-10.0% | $2.05M+5.0% | $1.95M-6.1% | |
| Pharmaceutical | $120.42M-1.2% | $121.91M+2.0% | $119.51M+1.2% | $118.11M+5.4% | $112.01M+8.7% | |
| D&A by Business | ||||||
| Diagnostics | $17.6M-9.2% | $19.37M-8.9% | $21.26M-6.3% | $22.68M-5.7% | $24.05M-8.3% | |
| Pharmaceutical | $72.73M+0.7% | $72.26M+0.3% | $72.03M0.0% | $72.03M+0.3% | $71.8M-0.2% | |
| Goodwill by Business | ||||||
| Diagnostics | $653.77M0.0% | $653.77M-7.9% | $710.03M-7.3% | $766.3M-6.6% | $820.59M-6.2% | |
| Pharmaceutical | $1.28B— | —— | —— | —— | —— | |
| Cost of Goods Sold by Business | ||||||
| Diagnostics | $278.98M-9.2% | $307.35M-5.0% | $323.62M-8.1% | $352.06M-6.6% | $376.75M-6.3% | |
| Pharmaceutical | $93.07M-0.6% | $93.59M+1.9% | $91.88M-3.4% | $95.16M+1.7% | $93.59M+1.2% | |
| Amortization Of Intangible Assets by Business | ||||||
| Diagnostics | $11.09M-9.9% | $12.3M-10.5% | $13.74M-6.4% | $14.69M-6.3% | $15.67M-7.4% | |
| Pharmaceutical | $65.91M+0.5% | $65.59M+0.2% | $65.44M+0.1% | $65.39M0.0% | $65.39M-0.5% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Diagnostics | $0— | $0— | $0— | $0— | $0— | |
| Goodwill Impaired Accumulated Impairment Loss by Business | ||||||
| Diagnostics | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | |
| Pharmaceutical | $46.79M— | —— | —— | —— | —— | |
| Revenue by Product | ||||||
| Rayaldee | $59.08M-0.5% | $59.39M-4.8% | $62.37M-1.6% | $63.36M-5.8% | $67.25M-3.0% | |
| Transfer Of Intellectual Property And Other | $81.4M+2.1% | $79.7M-10.6% | $89.11M+6.6% | $83.58M+3.3% | $80.92M+4.5% | |
| Cost of Goods Sold by Product | ||||||
| Product | $93.07M-0.6% | $93.59M+1.9% | $91.88M-3.4% | $95.16M+1.7% | $93.59M+1.2% | |
| Service | $278.98M-9.2% | $307.35M-5.0% | $323.61M-8.1% | $352.06M-6.6% | $376.75M-6.3% | |
| Revenue by Geography | ||||||
| CL | $62.71M+0.5% | $62.38M+2.5% | $60.88M-3.5% | $63.09M-2.5% | $64.69M-0.5% | |
| ES | $28.33M+6.0% | $26.72M+1.6% | $26.31M+0.2% | $26.27M+3.4% | $25.41M+3.2% | |
| IE | $55.6M+8.2% | $51.4M+9.1% | $47.12M+1.2% | $46.55M+4.3% | $44.65M-7.7% | |
| IL | $450K-14.0% | $523K-60.6% | $1.33M-4.0% | $1.38M-17.9% | $1.69M-4.9% | |
| MX | $26.23M+2.8% | $25.52M+4.1% | $24.51M+4.7% | $23.4M+1.7% | $23.01M-3.6% | |
| Other Countries | $4.43M+3.8% | $4.27M+5.8% | $4.04M+9.1% | $3.7M+6.1% | $3.49M+11.6% | |
| US | $403.36M-7.5% | $436.06M-8.8% | $477.89M-4.4% | $499.63M-5.1% | $526.47M-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Opko Health break its business down?
- Opko Health (OPK) reports gross profit by business across 2 parts — Diagnostics and Pharmaceutical. Each is extracted from the segment footnotes and tracked over time.
- Where does Opko Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Opko Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
